Bernstein analyst William Pickering initiated coverage of Regeneron with an Outperform rating and $1,125 price target. Despite a “cautious stance on Eylea,” the firm argues that Dupixent and oncology growth justify upside in the stock, says the analyst, who models 13% EPS growth from FY24-FY27, calling this out as “one of the best in the industry.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
- Regeneron published one-year results from PULSAR, PHOTON, met primary endpoint
- EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
- 2seventy bio: Close of asset sale to Regeneron seen in 1H24
- Regeneron price target raised to $1,184 from $1,096 at RBC Capital
